PBKR03

PBKR03 is an investigational gene therapy developed for the treatment of early-infantile Krabbe disease, a rare and severe pediatric lysosomal storage disorder caused by mutations in the GALC gene, which encodes the enzyme galactosylceramidase. The absence or deficiency of this enzyme leads to toxic accumulation of psychosine, resulting in widespread demyelination and neurodegeneration affecting both central and peripheral nervous systems. PBKR03 utilizes a next-generation proprietary adeno-associated virus serotype hu68 (AAVhu68) vector to deliver a functional copy of the human GALC gene via intra-cisterna magna administration. Preclinical studies have demonstrated that PBKR03 can restore myelination, normalize nerve conduction velocity, reduce psychosine levels, and improve survival in animal models. The therapy has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA[1][2][3][5][7].